Overview

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This prospective, naturalistic, open label study will test the hypothesis that Depakote is correlated with a reduction in elevated Cohen-Mansfield Agitation Index (CMAI) verbal and physical agitation and aggression scales over a 6-week period among patients with elevated scores on those scales, and that these positive results can be achieved with fewer side effects than with other agents. In addition, patients will be rated with respect to changes in the Clinical Global Impression (CGI) at baseline, week 1, 3, and 6 and the Neuropsychiatric Inventory (NPI) at baseline and week 6.
Phase:
Phase 1
Details
Lead Sponsor:
Hearthstone Alzheimer Care
Collaborator:
Abbott
Treatments:
Antipsychotic Agents
Valproic Acid